On November 7, I asked whether California’s A/M license split was enough if the DEA’s Minnesota reasoning came west. The answer may be that it doesn’t matter. As Highly Objective flagged on November 17, Marijuana Moment reports that the DEA has sent orders to show cause to at least some businesses in California, Delaware, Illinois, North Dakota, Oregon and Washington, D.C. The reported text of the California order doesn’t address the split. It targets something no license split can change.
California Tried to Make Room
After April’s federal rescheduling order, DCC adopted the A/M split on June 4, reasoning that separate licenses “may allow the medicinal entity to register” while preserving the adult-use business. According to DCC’s readoption finding, 95 businesses have split their licenses, and DCC filed to readopt the rule on November 16. Separation anticipated the concern the DEA later made central in Minnesota and Illinois: dual licensing.
In California, the Issue Is Patients
But the California order turns on patients. It says California lets dispensaries serve patients who present a physician’s “written documentation,” citing Health and Safety Code § 11362.715. Under 21 C.F.R. § 1301.13(k)(5), a certification suffices only if it is signed and dated the day issued and identifies the patient and the practitioner. Because California requires no such document, the order concludes that the DEA “cannot register any medical marijuana dispensary operating under California’s state law regime.”
The DEA cites the wrong provision for retail sales. Section 11362.715 governs county identification cards. Dispensary sales fall under DCC’s retail rule, Cal. Code Regs., tit. 4, § 15404(b), which requires a “valid physician’s recommendation.” But the DEA’s larger point stands. The California rule doesn’t require a recommendation to contain what federal (k)(5) lists, and the Compassionate Use Act allows recommendations to be oral under § 11362.5(d).
Is Registration Out of Reach?
For any single California business, it may be. Gillian Schauer of the Cannabis Regulators Association writes that the orders all say the DEA cannot admit any applicant operating under the state’s regime. No operator can cure that alone. A cure would have to come from DCC, for example by requiring (k)(5)-style recommendations for medicinal sales, or from the Legislature, and nothing guarantees the DEA would accept either. The order puts 491 California dispensary applications in doubt, and the 290 manufacturer and distributor applicants ultimately need registered dispensaries to sell to. In my September Chambers overview, I noted the “impossible choice” DCC described for licensees weighing registration. For now, the choice belongs to Sacramento and the DEA.
What It Means for Your Company
Whether to keep pursuing registration is a business-judgment call. Managers and directors should decide it on a record, with their reasoning in the minutes, especially where minority owners or lenders paid for the separation.
Deal terms need to catch up, too. Organigram’s November 12 material change report on its Aurora acquisition shows one approach: either party may extend the May 2, 2027 outside date twice, by 90 days each, if certain regulatory approvals are still pending. California deals need a representation on the target’s DEA status, a covenant on who decides whether to request a hearing, and a price adjustment or walk right if registration is denied.
What to Do Now
The checklist in my November 7 post still applies, including the November 29 supply-chain deadline. If an order arrives, request a hearing within 30 days of receipt under 21 C.F.R. § 1301.43, or risk default. Document the patient records you collect today, and review your operating agreement and pending deals for how DEA risk is allocated.
My corporate law practice advises California cannabis companies on entity structure, governance and M&A. If this order affects your structure or a pending deal, I advise on DEA registration strategy and deal terms for exactly these situations.
Posted By
Shay Aaron Gilmore is a California cannabis and hemp business attorney based in San Francisco, serving operators, investors, and cannabis startups across California. He advises clients on DCC regulatory compliance, cannabis licensing, corporate formation, intellectual property, commercial contracts, and administrative law proceedings. Recognized by the Daily Journal as a Top 20 Cannabis Lawyer in California and by Super Lawyers® as a Top 100 Northern California attorney, he is a leading voice in California cannabis and hemp law.
- Shay Aaron Gilmore
